Key result
Adding fenofibrate to rosuvastatin linked to ~2.1 mmol/L reduction in fasting triglycerides.
Why the study?
Real-world Vietnamese data on adding fenofibrate to rosuvastatin in patients with marked hypertriglyceridaemia and high cardiovascular risk are scarce.
Does adding fenofibrate 145 mg to ongoing rosuvastatin reduce fasting triglycerides over 6 months in adults at high or very high cardiovascular risk with mixed dyslipidaemia?
Observational (n=34)
No
Does adding fenofibrate 145 mg to ongoing rosuvastatin reduce fasting triglycerides over 6 months in adults at high or very high cardiovascular risk with mixed dyslipidaemia?
In high-risk Vietnamese patients with mixed dyslipidaemia on rosuvastatin, adding fenofibrate 145 mg significantly lowered triglycerides and raised HDL-C over 6 months without major safety signals, though few patients achieved the <1.7 mmol/L triglyceride target.
Answers are grounded in this paper and cite their sources.
Provides scarce real-world Vietnamese data on fenofibrate add-on; leaves open whether it improves cardiovascular outcomes in randomized trials.
Real-world Vietnamese data on fenofibrate add-on in marked hypertriglyceridaemia are scarce. This single-arm longitudinal observational study described the lipid changes and safety after adding fenofibrate 145 mg to ongoing rosuvastatin in adults at high or very high cardiovascular risk with fasting triglycerides (TG)≥1.7 mmol/L at Vinmec Da Nang International General Hospital, enrolled May-December 2025. Lipids and safety parameters were measured at baseline (T0), 3 (T1) and 6 months (T2); the analysis included 34 of 38 enrolled patients who remained adherent with complete laboratory data. Patients (76.5% male; aged 56.6±14.0 years) had a median baseline TG of 4.96 [3.34-8.18] mmol/L. TG fell to 2.27 [1.42-3.85] at T1 and 2.73 [2.11-3.77] mmol/L at T2 (both p<0.001); the absolute change from T0 to T2, the primary outcome, was −2.08 mmol/L (Hodges-Lehmann estimate, 95% CI −3.43 to −1.20), with median individual reductions of 51.8% and 36.2%, respectively. Attainment of TG<1.7 mmol/L was 32.4% at T1 (p = 0.001) and 14.7% at T2 (p = 0.063). HDL-C increased at T1 and T2 (p = 0.039 and 0.043), whereas LDL-C was unchanged (p = 0.383 and 0.225). Post hoc, rosuvastatin use >4 weeks before add-on was associated with lower 6-month TG (p = 0.047), but not robustly (p = 0.068 after excluding one influential observation). Among the 38 exposed patients (36 with follow-up laboratory data), no myopathy, hepatotoxicity or discontinuation attributed to an adverse effect was documented through the last available contact; creatinine rose at T1, with a smaller, non-significant difference from baseline at T2. In this single-centre cohort, adding fenofibrate was associated with lower TG and higher HDL-C over 6 months, but few patients reached the TG target and cardiovascular outcomes were not assessed.
No takes yet. Share an insight, caveat, or question.
Hien et al. (2026) conducted an observational in Mixed dyslipidaemia / marked hypertriglyceridaemia in high or very high cardiovascular risk (n=34). Fenofibrate 145 mg add-on to rosuvastatin vs. Baseline (single-arm study) was evaluated on Absolute change in fasting triglycerides from baseline to 6 months (Hodges-Lehmann estimate -2.08 mmol/L, 95% CI -3.43 to -1.20, p=<0.001). Adding fenofibrate to rosuvastatin reduced fasting triglycerides by 2.08 mmol/L over 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: